-8%

HYACORP BODY CONTOURING MLF1, 1 x 10ml

120.00 110.00

  • Format: 1 x 10 ml
  • Applicable by injection by a certified professional

Used for:

  • increase in volume and correction of the shape of the buttocks and hips;
  • volume increase and correction of the shape of the legs;
  • increase in volume and correction of the shape of calves;
  • correction of atrophic skin changes (injuries and operations);
  • correction of changes associated with inadequate redistribution of the volume of soft tissues or its complete loss.
Description

HYACORP BODY CONTOURING MLF1

HYACORP MLF1 is an absorbable skin implant with a high level of purity. It is a medical device intended for single use only and is produced from a hyaluronic acid of non-animal origin.

HYACORM MLF1 is specially designed for the body contouring and shaping.

Composition

1ml of HYAcorp MLF1 contains:

    • Hyaluronic acid 2.0 mg
    • Hyaluronic acid cross-linked 20.0 mg
    • Sodium chloride 6.9 mg
    • Water for injection ad 1.0 ml
    • Particle size 200-350 microns

Product Application

HYACORP MLF1 is intended to be used as a means of restoring lost volume and contouring body surfaces. The depth of the injection can vary depending on the treatment site, the subcutaneous application and the supraperiostal application.

      • Buttocks
      • Calves
      • Correction of concave deformities

HYAcorp MLF1 and HYAcorp MLF2
can be combined with each other for the best results of correction and alignment of the skin texture.

Indications:

      • increase in volume and correction of the shape of the buttocks and hips;
      • volume increase and correction of the shape of the legs;
      • increase in volume and correction of the shape of calves;
      • correction of atrophic skin changes (injuries and operations);
      • correction of changes associated with inadequate redistribution of the volume of soft tissues or its complete loss.

Benefits:

      • minimally invasive method;
      • the ability to influence sexual feelings;
      • reversibility;

Methodology:

under local anesthesia;
the injection zone was treated with an antiseptic;
periurethral injection of 3 to 5 ml of HYAcorp MLF1 superficially into the mucosa with a retrograde injection technique.

Format:

1 syringe of 10 ml